Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › riluzole

riluzole

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of riluzole

17 trials tracked of riluzole: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 602 citations.

17Trials tracked
5Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 4 Phase 3 1 Phase 2 10 Phase 1 1 Other / NA 1
  1. Phase 4 Research Study for Major Depressive Disorder: Investigation of Glutamate Medications Completed · 602 cited
  2. Phase 3 Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS Completed · 137 cited
  3. Phase 4 Riluzole in Fragile X Syndrome Completed · 65 cited
  4. Phase 4 Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation Completed
  5. Phase 4 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed
  6. Phase 2 Neuroprotection With Riluzole Patients With Early Multiple Sclerosis Completed
Show 11 more trials
  1. Phase 2 Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed
  2. Phase 2 Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders Completed
  3. Phase 2 Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Completed
  4. Phase 2 Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS) Completed
  5. Phase 2 Riluzole in Mild Alzheimer's Disease Completed
  6. Phase 2 Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD) Completed
  7. Phase 2 A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression Completed
  8. Phase 2 Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) Completed
  9. Phase 2 Efficacy and Tolerability of Riluzole in Treatment Resistant Depression Completed
  10. Phase 1 A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD) Completed
  11. N/A Riluzole in the Treatment of Bipolar Depression Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Glutamatergic agents show preclinical promise in Multiple Sclerosis but fail in clinical trials
Neurology Sys. Review
Glutamatergic agents show preclinical promise in Multiple Sclerosis but fail in clinical trials Laboratory tests show promise for multiple sclerosis but face hurdles
This narrative review examines the efficacy of glutamatergic agents in experimental autoimmune encephalomyelitis models versus human clinica…
Certain drugs showed success in lab models for multiple sclerosis, but these same medicines failed to work during actual human clinical tria…
Frontiers Aug 11, 2026
Masitinib 4.5 mg/kg/day associated with survival in ALS post-hoc analysis
Neurology RCT
Masitinib 4.5 mg/kg/day associated with survival in ALS post-hoc analysis This Drug Could Add Nearly Two Years to ALS Life
This post-hoc analysis of a randomized, double-blind, placebo-controlled trial in 130 ALS patients found that masitinib 4.5 mg/kg/day was as…
A new look at data suggests a specific drug might significantly extend life for some people with ALS.
medRxiv Apr 19, 2026